血清HBsAg阳性的肺结核患者抗痨治疗引起病毒再激活和药物性肝损伤发生影响因素分析*

doi:10.3969/j.issn.1672-5069.2025.01.018

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (1): 68-71.doi: 10.3969/j.issn.1672-5069.2025.01.018

血清HBsAg阳性的肺结核患者抗痨治疗引起病毒再激活和药物性肝损伤发生影响因素分析^*

郭珍, 王欣, 牛攀霞

710100 西安市陕西省结核病防治院内二科(郭珍, 王欣);西安医学院第二附属医院感染病科(牛攀霞)

收稿日期:2023-08-02 出版日期:2025-01-10 发布日期:2025-02-07
通讯作者: 王欣,E-mail:15829310979@163.com
作者简介:郭珍,女,36岁,大学本科,主治医师。E-mail:guozhen512@163.com
基金资助:
^*陕西省科技厅重点研发计划项目(编号:2020SF-105)

Factors influencing the occurrence of hepatitis B viral reactivation and drug-induced liver injury during anti-tuberculosis treatment in patients with serum HBsAg-positive pulmonary tuberculosis

Guo Zhen, Wang Xin, Niu Panxia

Section Two, Department of Internal Medicine, Provincial Tuberculosis Prevention and Treatment Hospital, Xi'an 710100, Shaanxi Province, China

Received:2023-08-02 Online:2025-01-10 Published:2025-02-07

摘要/Abstract

摘要： 目的分析血清HBsAg阳性的肺结核患者在抗结核治疗过程中病毒再激活和药物性肝损伤(DILI)发生的影响因素。方法 2021年1月～2022年12月我院诊治的血清HBsAg阳性肺结核患者120例,均接受标准的抗痨治疗,45例患者接受了恩替卡韦预防性抗病毒治疗。采用多因素Logistic回归分析抗结核治疗过程中病毒再激活和DILI发生的影响因素。结果在抗痨过程中,发生病毒再激活30例(25.0%);病毒再激活组均未接受预防性抗病毒治疗,年龄及长期饮酒、低蛋白血症和应用皮质激素占比分别为(43.5±6.2)岁、60.0%、66.6%和36.7%,均显著大于或高于未发生病毒再激活组【分别为(36.2±5.0)岁、17.7%、20.0%和11.1%,P＜0.05】;在抗痨过程中,发生DILI者45例(37.5%);DILI组长期饮酒和低蛋白血症占比分别为55.6%和62.2%,显著高于未发生DILI组(分别为12.0%和13.3%,P＜0.05),而接受预防性抗病毒治疗占比为22.2%,显著低于未发生DILI组的46.7%(P＜0.05);多因素Logistic回归分析显示,不接受抗病毒治疗、长期饮酒和低蛋白血症是血清HBsAg阳性肺结核患者抗结核治疗过程中病毒再激活的独立危险因素(P＜0.05),而长期饮酒、低蛋白血症和不抗病毒治疗是发生DILI的独立危险因素(P＜0.05)。结论血清HBsAg阳性的肺结核患者抗痨治疗过程中可能会发生病毒再激活和DILI,了解危险因素,及早做好预防和处理,可能能保证抗痨治疗的顺利进行。

关键词: 药物性肝损伤, 肺结核, HBsAg, 抗结核治疗, HBV再激活, 危险因素

Abstract: Objective The aim of this study was to analyze the factors influencing the occurrence of hepatitis B viral reactivation (HBV-RA) and drug-induced liver injury (DILI) during anti-tuberculosis treatment in patients with serum HBsAg-positive pulmonary tuberculosis (PT). Methods 120 patients with serum HBsAg-positive PT were encountered in our hospital between January 2021 and December 2022, and all received standardized anti-tuberculosis treatment. The preventive entecavir antiviral treatment was given in 45 patients. The influencing factors for HBV-RA and DILI occurrence were analyzed by multivariate Logistic regression. Results The HBV-RA occurred in 30 cases (25.0%)during anti-tuberculosis treatment and all of them didn’t received entecavir antiviral treatment; the age, percentages of drinking hobby, hypoalbuminemia and administration of steroid in patients with HBV-RA were(43.5±6.2)yr, 60.0%, 66.6% and 36.7%, all significantly greater or higher than [(36.2±5.0)yr, 17.7%, 20.0% and 11.1%, respectively, P＜0.05] in those without HBV-RA, all of whom received entecavir therapy; during anti-tuberculosis treatment, the DILI occurred in 45 cases (37.5%); the percentages of drinking hobby and hypoalbuminemia in patients with DILI were 55.6% and 62.2%, much higher than 12.0% and 13.3%, respectively, P＜0.05), while the percentage of persons receiving antiviral therapy was 22.2%, much lower than 46.7%(P＜0.05)in those without DILI; the multivariate Logistic regression analysis showed that no antiviral treatment, drinking hobby and hypoalbuminemia were the independent risk factors for the HBV-RA (P＜0.05) and the drinking hobby and hypoalbuminemia were the independent risk factors for DILI occurrence in patients with serum HBsAg positive PT(P＜0.05). Conclusion The HBV-RA and DILI could occur during antituberculosis treatment in patients with serum HBsAg positive PT, which might be carefully prevented and managed appropriately in clinical practice.

Key words: Drug-induced liver injury, Pulmonary tuberculosis, HBsAg, Anti-tuberculosis treatment, Hepatitis B viral reactivation, Risk factors

郭珍, 王欣, 牛攀霞. 血清HBsAg阳性的肺结核患者抗痨治疗引起病毒再激活和药物性肝损伤发生影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 68-71.

Guo Zhen, Wang Xin, Niu Panxia. Factors influencing the occurrence of hepatitis B viral reactivation and drug-induced liver injury during anti-tuberculosis treatment in patients with serum HBsAg-positive pulmonary tuberculosis[J]. Journal of Practical Hepatology, 2025, 28(1): 68-71.

参考文献

[1] Pang Y, An J, Shu W, etal. Epidemiology of extrapulmonary tuberculosis among inpatients, China, 2008-2017. Emerg Infect Dis, 2019, 25(3):457-464.
[2] 崔怡然, 宇传华. 基于全球视角下的中国结核病负担现状与趋势分析. 中华疾病控制杂志, 2020, 24(3): 258-283.
[3] 何昱颖, 胡屹, 陈玮, 等. 2014年至2018年贵州省利福平耐药结核病的危险因素及治疗转归分析. 中华传染病杂志, 2021, 39(5): 289-294.
[4] Taye H, Alemu K, Mihret A, et al. Global prevalence of mycobacterium bovis infections among human tuberculosis cases: systematic review and meta-analysis. Zoonoses Public Health, 2021, 68(7): 704-718.
[5] Khan AF, Sajjad A, Mian DA, et al. Co-infection with hepatitis B in tuberculosis patients on anti-tuberculosis treatment and the final outcome. Cureus, 2021, 13(4):e14433.
[6] 张洋婷, 卢学昭, 李晓娜, 等. 肺结核合并糖尿病患者药物性肝损伤影响因素分析. 中国防痨杂志, 2022, 44(1): 64-70.
[7] 中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10): 733-749.
[8] Gał zka M, Didkowska A, Anusz K, et al. A review of tuberculosis and parasitic disease co-infection in ungulates, with regard to the potential threat to European bison (bison bonasus). Pol J Vet Sci, 2023, 26(1): 155-161.
[9] Cöllü AY, Ucarman N, Bayhan GI. Complicated clinical course of zoonotic tuberculosis due to mycobacterium Caprae:a case report and literature review. Int J Mycobacteriol, 2022, 11(4): 466-468.
[10] Cao J, Mi Y, Shi C, et al. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform. Biochem Biophys Res Commun, 2018, 497(2):485-491.
[11] Liu L, Li X, Huang C, et al. Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs. Expert Opin Drug Metab Toxicol, 2020, 16(6):527-537.
[12] Liu W, Lu L, Pan H, et al. Heme oxygenase-1 and hemopexin gene polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity in China. Pharmacogenomics, 2022, 23(7):431-441.
[13] Ali N, Gupta N, Saravu K. Malnutrition as an important risk factor for drug-induced liver injury in patients on anti-tubercular therapy: an experience from a tertiary care center in South India. Drug Discov Ther, 2020, 14(3):135-138.
[14] Moosa MS, Maartens G, Gunter H, et al. A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury. Clin Infect Dis, 2021, 73(9):e3377-e3383.
[15] Chen R, Wang J, Zhang Y, et al. Key factors of susceptibility to anti-tuberculosisdrug-induced hepatotoxicity. Arch Toxicol, 2015, 89(6):883-897.
[16] Chang TE, Huang YS, Chang CH, et al. The susceptibility of anti-tuberculosisdrug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis. J Chin Med Assoc, 2018, 81(2):111-118.
[17] Liu X, Ren S, Zhang J, et al. The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. Ann Palliat Med, 2021, 10(6):6518-6534.
[18] Ambade A, Lowe P, Kodys K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology, 2019, 69(3):1105-1121.
[19] Haller C. Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations. Kidney Blood Press Res, 2005, 28(5-6):307-310.
[20] Otaki Y, Watanabe T, Takahashi H, et al. Comorbid renal tubular damage and hypoalbuminemia exacerbate cardiac prognosis in patients with chronic heart failure. Clin Res Cardiol, 2016, 105(2):162-171.

血清HBsAg阳性的肺结核患者抗痨治疗引起病毒再激活和药物性肝损伤发生影响因素分析^*

Factors influencing the occurrence of hepatitis B viral reactivation and drug-induced liver injury during anti-tuberculosis treatment in patients with serum HBsAg-positive pulmonary tuberculosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	莫伟斌, 欧阳婉爱, 黄晓涵, 何鼎醇. 80例药物性肝损伤患者临床特征与预后分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 72-75.
[2]	孙敏, 张倩, 徐刚, 王加林, 何振文. ACLF患者肺部感染发生率及预测因素分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 84-87.
[3]	李靖, 何海滨, 李春婷, 石磊. 230例药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 870-873.
[4]	周云松, 赵琦, 胡芳, 李叙颖, 崔峻松, 黄敬, 黄娜娜, 赵一鹏. 葛根素通过抑制AHR/氧化应激途径改善酮康唑诱导的大鼠肝损伤研究[J]. 实用肝脏病杂志, 2024, 27(5): 669-672.
[5]	冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.
[6]	张怀东, 雷宇, 周智. 失代偿期肝硬化合并肝外脓肿患者临床特点分析[J]. 实用肝脏病杂志, 2024, 27(5): 761-764.
[7]	廖敏君, 饶慧瑛. 脂肪性肝病相关肝细胞癌筛查和监测策略[J]. 实用肝脏病杂志, 2024, 27(4): 484-487.
[8]	潘劲劲, 谢琴秀, 许夕海, 郜玉峰, 李家斌. 药物性肝损伤患者血清抗核抗体阳性临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 543-546.
[9]	李勇, 张蕾, 吴幸福. 老年药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 547-550.
[10]	农晓黎, 陈菲, 詹浩洪, 罗婷, 曾碧丹. 体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 353-356.
[11]	郎平, 崔闪闪, 赵艳. 药物性肝损伤患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 382-385.
[12]	王修琪, 张裕, 吴一凡, 董成宾, 岳振东, 王成. TIPS术治疗的肝硬化患者肝性脊髓病临床特征及其影响因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 410-413.
[13]	朱春芬, 任春霖, 郭霞. 肝硬化性心肌病患者临床特点、心电图表现和危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 414-417.
[14]	师阿盟, 何鑫, 王莹, 姜珏, 周琦, 王倩, 史海涛, 董蕾. 非肥胖人群胆结石检出率与危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 458-461.
[15]	梁丹丹, 江建宁, 黄锦妮, 龙诗雨, 董国珍, 苏曼, 李继娇, 滕春玲, 张萍, 苏明华. 219例药物性肝损伤患者临床特征和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 210-213.